Long term outcomes and mutations in patients with mantle cell lymphoma (MCL) who discontinued ibrutinib have not been described. Using deep targeted next generation sequencing, we performed somatic mutation profiling from 15 MCL patients (including 5 patients with paired samples; before and after progression on ibrutinib). We identified 80 patients with MCL who discontinued ibrutinib therapy for various reasons. Median follow-up after ibrutinib discontinuation was 38 months. The median duration on ibrutinib was 7Á6 months. Forty-one (51%) patients discontinued ibrutinib due to disease progression/transformation, 20 (25%) for intolerance, 7 (9%) due to patient choice, 5 (6%) for stem cell transplant, 4 (5%) due to second cancers and 3 (4%) other causes. The median survival after ibrutinib was 10 and 6 months for disease progression and transformation, respectively, and 25 months for patients with ibrutinib intolerance. Overall, BTK mutations were observed in 17% patients after progression on ibrutinib. Notably, TP53 alterations were observed after progression in 75% patients. Among the 4 patients with blastoid transformation, 3 (75%) had NSD2 mutations (co-existing with TP53). Ibrutinib-refractory MCL patients had a short survival. Demonstration of TP53 and NSD2 mutations in patients who developed blastoid transformation and ATM and TP53 mutations in patients who progressed, opens the door for future investigations in ibrutinib-refractory MCL.
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B-cell receptor (BCR) signalling pathway plays a major role in the growth and survival of mantle cell lymphoma (MCL) cells (Saba et al, 2016) . Inhibition of Bruton tyrosine kinase (BTK) enzyme, a pivotal member of BCR signalling with ibrutinib (Wang et al, 2013) and acalabrutinib (Wang et al, 2018 ) is a major breakthrough in the treatment of patients with MCL. Ibrutinib is commonly used in the treatment of MCL as well as in small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL). A few reports have demonstrated that patients with MCL who progressed on ibrutinib have a poor survival (range 3-8 months) (Martin et al, 2016; Cheah et al, 2015) . Patients with favourable disease characteristics prior to ibrutinib initiation and those with a durable response on ibrutinib were able to achieve remissions after ibrutinib failure (Martin et al, 2016) .
The optimal management of patients who progress on ibrutinib is unclear and clinical trials with drugs such as venetoclax (Davids et al, 2017; Jones et al, 2018) are ongoing.
The mechanisms of ibrutinib resistance and the relevance of clonal evolution are being studied in B cell lymphoid malignancies (Burger et al, 2016; Jayappa et al, 2017; Landau et al, 2017; Zhao et al, 2017; Hershkovitz-Rokah et al, 2018) . In contrast to SLL/CLL, where the primary mode of ibrutinib resistance is considered to be via BTK C481S and PLCG2 gene mutations (Ahn et al, 2017; Woyach et al, 2017) , studies in MCL (Chiron et al, 2014; Martin et al, 2016) and in follicular lymphoma (FL) (Jain et al, 2017) indicate that these mutations were uncommon in ibrutinib-resistant patients. Furthermore, the prognostic significance of somatic mutations in MCL is identified by whole genome and whole exome sequencing (Bea et al, 2013; Rahal et al, 2014) . TP53, NOTCH1 and NOTCH2 mutations were significantly associated with patient survival (Bea et al, 2013; Eskelund et al, 2017; Aukema et al, 2018) . In addition, mutations in chromatin modifier genes (Zhang et al, 2014) , such as NSD2 (also termed WHSC1 or MMSET), and the activation of alternative nuclear factor (NF)-jB pathway signalling by MAP3K14 or NIK enzyme and/or recurrent mutations in BIRC3, TRAF2 and CARD11 genes were demonstrated to have pathological relevance in MCL progression and ibrutinib resistance (Rahal et al, 2014; Wu et al, 2016) .
In the current study, we evaluated the long-term outcomes and survival of patients after discontinuing ibrutinib. In addition, we explored the mutational profile in a subset of patients who developed disease progression and/or disease transformation on ibrutinib treatment.
Patients and methods
Overall, 159 patients received ibrutinib-based therapies at our centre between February 2011 and March 2017. Charts from 80 (50%) patients who discontinued ibrutinib for various reasons were reviewed (76 were relapsed/refractory and 4 were treated with frontline ibrutinib). We analysed only those 80 patients who discontinued therapy while rest of the patients continued on ibrutinib. All patients provided informed consent to obtain their information from clinical charts and perform molecular studies. The protocol was approved by the Institutional Review Board in accordance with the Declaration of Helsinki. All clinical trials were registered at clinicalTrials.-gov. Clinical characteristics of the patients who discontinued ibrutinib, reasons for discontinuation, follow-up, outcomes and salvage treatments were evaluated. We also reviewed the histopathology findings from the bone marrow (BM), lymph node (LN) or involved tissues biopsies/fine needle aspirations (FNA) and peripheral blood (PB). Kaplan-Meier survival postibrutinib was calculated from the date of ibrutinib discontinuation to the date of last follow-up or the date of death. Duration of ibrutinib therapy was calculated from the date of ibrutinib initiation to the date of discontinuation. Log rank test was used to estimate the time to event outcomes.
Molecular analysis
Targeted next-generation sequencing based mutation analysis. DNA was extracted from tumour from formalin-fixed paraffin-embedded blocks or BM aspirates (available and evaluable samples; n = 20, 8 prior to starting ibrutinib and 12 at the time of disease progression or transformation). In a subset of patients (Patients 5, 6, 8, 12 and 15) , sequencing at both time points was done (5 pairs; baseline and at progression). Details of the methods used in the sequencing are provided in Appendix S1. This high throughput targeted high coverage next generation sequencing (NGS)-based assay interrogated a panel of 300 genes relevant in haematological malignancies (Table SI) . The captured libraries were sequenced on a 2 9 76 bp paired-end on a HiSeq 4000 platform (Illumina Inc., San Diego, CA, USA). The sequencing data in FASTQ format were aligned to human reference genome (hg19) using the Burrows-Wheeler Alignment (BWA) tool (v0.7.5; http://ma q.sourceforge.net). The aligned BAM files were then subjected to duplication marking, realignment and base recalibration using Picard (v1.112; http://broadinstitute.github.io/picard/) and GATK (v3.1-1; https://software.broadinstitute.org/gatk/ documentation/tooldocs/3.8-0/org_broadinstitute_gatk_tools_ walkers_genotyper_UnifiedGenotyper.php) software tools.
Results

Patients and disease characteristics
Overall, 80 patients discontinued ibrutinib over a period of about 6 years. Four (5%) received frontline ibrutinib and 76 (95%) were treated for relapsed/refractory disease. Fortyeight patients (60%) received ibrutinib alone, 28 with rituximab (35%) and 4 with carfilzomib (5%). The median follow-up time from the date of ibrutinib commencement was 62 months. The median duration of ibrutinib therapy in all patients was 8 months (range 0Á3-59 months) and the median number of cycles of ibrutinib treatment was 9 (1-61).
The patient characteristics at the time of ibrutinib initiation included: median age 69 years (range 35-86), high MCL International Prognostic Index (MIPI) score 45 (56%), high Ki67% (≥30%; n = 33, 50%), blastoid/pleomorphic morphology in 20 (25%) and median number of prior therapies was 2 (range 1-11).
Causes of ibrutinib discontinuation included: progression (n = 41, 51%, including 5 patients with biopsy-proven blastoid transformation), intolerance (n = 20, 25%, 6 recurrent infections, 6 multiple toxicities, 4 atrial fibrillation and 4 bleeding/easy bruising), patient choice (n = 7, 9%), stem cell transplant (SCT; n = 5, 6%), second cancers (n = 4, 5%) (2 with non-small cell lung cancer, one therapy-related myelodysplasia, one gastro-oesophageal junction cancer) and other causes (n = 3; 4%; 1 financial problems, 1 died of unknown reasons, one patient went elsewhere for treatment). Duration of ibrutinib intake in patients who progressed (without Patients characteristics at the time of ibrutinib initiation according to cause of discontinuation are summarized in Table I . Of note, the group of patients whose disease progressed had higher proportions of patients with high MIPI score (63%), higher median Ki67% (45%) and blastoid morphology (36%) compared with other aetiologies. Among progressed patients, 5 (12%) were considered as transformed MCL (classic at ibrutinib start to blastoid morphology at progression on ibrutinib). The characteristics of 41 patients who progressed/transformed according to post-ibrutinib survival are shown in Table SII . Of note, 14/41 (34%) had postibrutinib survival ≤6 months. Among these 14 patients, the median age was 71 years (54-86), 5 had blastoid morphology at ibrutinib start, median Ki67% was 50% (15-100), 9/14 (64%) had high MIPI risk score and 12 patients had died at the time of last follow-up. Four patients who transformed were included in these 14 patients.
Patient outcomes
The median follow-up after ibrutinib discontinuation (for all reasons) was 38 months. Overall, median post-ibrutinib survival was 11 months (excluding 8 patients who discontinued due to SCT and/or other causes) (Fig 1A) , 3-year survival was 25%. Twenty-seven patients were alive and 45 had died. Causes of death within each aetiology of discontinuation were -progression/transformation (31 deaths; all due to progression except one who died because of pancreatic cancer), intolerance (9 deaths; 3 for disease progression and 6 lost to follow-up/ unknown reasons), 2 deaths were due to second cancers, 1 for unknown reasons, 1 due to disease progression after SCT, 5 patients died after discontinuing ibrutinib by patient choice (1 due to other cancer, 1 disease progression, 3 lost to follow-up).
Survival was compared according to the aetiology of discontinuation (excluding 8 patients who discontinued due to SCT and/or other causes) (Fig 1C) , patients with disease progression/transformation had inferior survival of 9 months, (P = 0Á14) compared to those with various reasons (25 months for intolerance, 12 months for second cancers, 28 months for patient choice). For intolerance, 11 remained in observation in remission and 9 were subsequently treated. There was no statistically significant difference in patients who progressed versus those who transformed; median survival was 10 vs. 6 months (P = 0Á66, Fig 1B) . The cumulative incidence of ibrutinib discontinuation over time showed that discontinuation due to disease progression/transformation continued to increase over time (P < 0Á0001; Fig 1D) . Discontinuation beyond 18 months was mainly due to disease progression/transformation, while discontinuation due to other aetiologies was mainly clustered in the first 12 months of ibrutinib therapy. Median survival was not reached for patients who discontinued due to SCT or due to other reasons (not shown).
Outcome and management of patients who progressed/ transformed (n = 41)
Thirty-six patients received salvage treatments and 5 remained untreated (3 died with disease progression and 2 were lost to follow-up), all of which are summarized in Table SII . Among these 36 with salvage treatments, 27% responded and the median therapies after discontinuation was 2 (range 1-6). Salvage treatments included rituximab with hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cyatarabine; R-HCVAD, n = 6), radiation with intensive chemotherapy (n = 6), bendamustine-based (n = 5), lenalidomide-based (n = 4), bortezomib-based (n = 3), rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; R-CHOP, n = 3), radiation alone (n = 3), rituximab with etoposide, methylprednisolone, cytarabine, cisplatin (R-ESHAP) with allogeneic SCT (allo-SCT; n = 1), lenalidomide with rituximab and proteasome inhibitor (LR-P; n = 2), one phosphoinositide 3-kinase inhibitor and 2 patients were lost to follow-up after miscellaneous therapies. Overall, 10 patients were alive and 26 died. Among the ten alive, 6 remain in complete remission [CR; bendamustine with rituximab (BR) followed by allo-SCT, BR followed by restart of ibrutinib with rituximab, R-HCVAD followed by venetoclax, R-ESHAP followed by allo-SCT, LR-P, LR followed by chimeric antigen receptor T cell therapy] and one patient each had stable disease on LR-P, partial response on BR, progressive disease on BR and nonresponder on R-CHOP. Among the 26 patients who died after salvage treatments, 23 were non-responders and continued to progress and 3 patients responded to R-HCVAD followed by SCT and progressed (n = 1), BR followed by CR and disease progression (n = 1), LR-P achieved CR but died due to pancreatic cancer in CR. In the subset of 5 transformed patients, 2 were alive (each received BR and achieved PR, BR with radiation followed by allo-SCT and remain in CR), 2 died with progression and one was lost to follow-up.
Mutation profile in a subset of patients with available samples
Fifteen patients [including 5 patients with paired samples (before and after progression on ibrutinib) and 10 patients which were unpaired; 3 at baseline and 7 after progression on ibrutinib] underwent sequencing, yielding a mean on-target coverage of~7009. Figure 2 is a flow diagram showing the patients whose samples underwent sequencing. Figure 3 shows the recurrent somatic mutations detected in more than 1 sample according to the patient identification (8 baseline and 12 at progression). Fourteen of the tested genes were altered in two or more patients (Fig 3) . BTK hotspot mutations were identified only in two patients (both at progression, 17%; C481S and C481R) and EP300 in two patients (one at baseline and another at progression). None of the samples had mutations in PLCG2 or BIRC2/3, TRAF2/3 or MYD88 genes. Five genes, TP53, ATM, NSD2 (WHSC1), CDKN2A and UBR5 were altered in a third or more samples. Notably, the TP53 alterations were either truncating or deleterious missense with one loss of heterozygosity (LOH) and were observed mainly at progression in 9/12 (75 %), suggesting that the loss of function of TP53 may play an important role in driving MCL progression. Only one patient had TP53 mutation prior to starting ibrutinib (Patient 15) and the variant allele fraction (VAF) in the paired sample from the same patient showed a rise in VAF at the time of progression (Fig 4B) . Alterations in ATM, NSD2, CDKN2A and UBR5 were detected at both baseline (n = 4, 2, 4 and 2 respectively) and at the time of disease progression (n = 9, 4, 7 and 4 respectively) with no statistical difference between time points. Interestingly, among the 4 patients with blastoid transformation (Fig 4B) , 3 (75%; P = 0Á02) had NSD2 mutations (p.E1099K) (co-existing with TP53 with a higher VAF in TP53 compared to NSD2). In one patient, after analysing the VAF of one baseline-progression paired sample, we found that the VAF of NSD2 dramatically increased at transformation (blastoid transformed MCLPatient 12) (Fig 4A) . Moreover, NSD2 mutations were mutually exclusive with UBR5 (P = 0Á031, Fisher's Exact test, two-tailed) and the UBR5 mutant tumours were either classic or de novo blastoid, suggesting a probable alternative mechanism of disease progression via UBR5 for non-blastoid progressed tumours. All UBR5 mutations were also truncating or deleterious missense. We also noted CDKN2A alterations in 7 patients at progression (4 had LOH, 2 deep deletions and one with missense mutation with LOH). Using functional prediction algorithms, both missense mutations of NOTCH2 and the other missense mutation of NOTCH1 are predicted to be functionally deleterious, suggesting their potential significance. Apart from one patient with transformation (Patient 12) showing the emergence of TP53, NSD2 and MEF2B mutations at blastoid transformation and 3 patients showing an increase in VAF in TP53 mutations (Patients 6, 12 and 15; Fig 4C) , we did not observe any other particular trend for the VAF of mutations in the 5 patients with baseline-progression paired samples (Fig 4) . Details of mutation profile from individual samples are in (Table SIII) .
Discussion
This report describes the long-term outcomes and mutation profile in patients with MCL after discontinuing ibrutinib (median follow-up of >3 years after discontinuation). Overall, the median follow-up time from ibrutinib start was 62 months, which is by far the longest reported follow-up time for patients on ibrutinib therapy in MCL. Survival of patients after progression/transformation on ibrutinib remains poor and only a fraction of patients responded to subsequent therapies. Using targeted NGS in a subset of patients with available samples, we detected TP53 alterations in 75% of patients after progression on ibrutinib and NSD2 mutations were detected in 75% of patients with transformed MCL on ibrutinib therapy. BTK mutations were rarely detected at progression.
With an increase in our clinical experience with ibrutinib, our understanding of BTK resistance and outcomes in patients that are refractory to BTK inhibitors in lymphoid malignancies continues to improve. Ibrutinib-refractory lymphoid malignancies (Martin et al, 2016; Woyach, 2017) (MCL, SLL/CLL) are now a distinct therapeutic challenge. Our long term follow-up results, showing poor post-ibrutinib survival in MCL, are consistent with our previous report and another report from a different group (Cheah et al, 2015; Martin et al, 2016) . However, several differences were noteworthy in our report as compared to the earlier results by Martin et al (2016) which included only those patients who progressed on ibrutinib. Median follow-up after ibrutinib discontinuation in our report was >3 years and median duration of ibrutinib intake was 7Á6 months as compared to 4Á7 months in the study reported by Martin et al (2016) and the median survival in patients who progressed was 10 months in contrast to 3 months reported earlier (Martin et al, 2016) . Although the number of patients who progressed/transformed in our study was 41 (compared to 114 reported by Martin et al, 2016) , our study is from a single centre with a uniform follow-up strategy. Response rates to post-ibrutinib salvage treatments were similar, 27% in our report vs. 29% (Martin et al, 2016) . Post-ibrutinib survival in our study was 7 months longer in the current report as compared to the previous report (Martin et al, 2016) and this difference could simply be due to the differences in the types of salvage treatments administered and the longer follow-up time in our study. The bottom panel showed the relative proportions of six types of base substitutions that are represented in each tumour sample. ATM, TP53, NSD2, CDKN2A and UBR5 were observed in patients who progressed on ibrutinib while BTK mutations were seen in 2/12 patients at progression. NSD2 mutation was seen in 3 patients with transformed MCL. Gene alterations (mutations and loss of heterozygosity, LOH) preferentially observed in samples at progression (n = 12) included: CDKN2A (n = 7), SAMHD1 (n = 2), NOTCH1 (n = 1), NOTCH2 (n = 2), KMT2A (MLL1; n = 2), KMT2D (MLL2; n = 2), CCND1 (n = 2) and CARD11 (n = 1).
Long Term Outcomes After Ibrutinib in MCL
ª 2018 British Society for Haematology and John Wiley & Sons Ltd intensive chemoimmunotherapy followed by SCT and chimeric antigen receptor T cell therapy (CAR-T). Of note, one patient restarted ibrutinib with rituximab and achieved CR. Only one death occurred among the 5 patients who received SCT as first salvage after ibrutinib. These differences in outcomes may also represent an inherent heterogeneity among the patients enrolled in the different clinical trials. As expected, the group of patients who progressed or transformed had a higher proportion of patients who began with a high risk disease -blastoid morphology and a high Ki67%. In particular, among the blastoid transformed patients on ibrutinib, we noted that 5 patients had a trend for an inferior survival compared to those who progressed (untransformed). Disease transformation on ibrutinib is akin to that observed in patients with SLL/CLL (Jain et al, 2014) but largely remains unexplored. Interestingly, two transformed patients responded to bendamustine-based treatments (one received an allo-SCT) and both were alive at the time of last follow-up. However, with a limited number of transformed patients, it is difficult to reach firm conclusions.
Considering that ibrutinib is associated with clonal evolution over time (Burger et al, 2016; Landau et al, 2017) , it is possible that sub-clones with ibrutinib resistance accumulate over time under selection pressure and develop resistance, potentially explaining our finding of increasing cumulative incidence of patients who discontinued ibrutinib after disease progression over time. However, due to the lack of sequential samples over time (a limitation in obtaining biopsies or tissue material in MCL), we were unable to confirm this hypothesis.
With regard to other reasons for discontinuation, our results are consistent with previous reports on ibrutinib discontinuation Martin et al, 2016) . The reasons for intolerance to ibrutinib were similar to other reports (Cheah et al, 2015; Jain et al, 2015 Jain et al, , 2017 Wang et al, 2015; Martin et al, 2016) . In addition, 4 patients discontinued ibrutinib after developing second cancers and a few patients developed other cancers after discontinuing ibrutinib. Development of second cancers after ibrutinib treatment is entirely an area under exploration because most of these patients were in the relapsed/refractory MCL setting and received chemotherapies prior to ibrutinib; therefore based on our data, it is difficult to attribute second cancers on ibrutinib alone (Barista et al, 2002; Wang et al, 2015) .
In addition, we described a pattern of mutations associated with disease progression in a subset of patients with available samples at baseline and at progression on ibrutinib. In contrast to previous reports on ibrutinib resistance in SLL/CLL and similar to reports in MCL, (Chiron et al, 2014; Martin et al, 2016) we found that BTK mutations were not very common in ibrutinib-refractory MCL. Only two patients had BTK mutations at disease progression (none at baseline) and one was the C481R variant. The significance of variant BTK is possibly related to the catalytic state of BTK in response to a different amino acid substitution. None had PLCG2 mutations. Interestingly, we further noted that TP53 mutations were observed mainly at the time of disease progression (67% samples at progression) and 1/8 (12%) among the pre-ibrutinib samples. Also, the VAF of TP53 mutations increased in 3 patients with baseline-progression paired samples. This finding may be interesting as this suggested that clones of MCL cells harbouring TP53 mutations were probably driving ibrutinib resistance. A previous report also suggested that TP53 expression is linked to poor prognosis in MCL (Aukema et al, 2018) . Furthermore, NSD2 mutations were observed in 3 of 4 samples (concurrent with TP53) at the time of blastoid transformation, which is very interesting because NSD2-mutated MCL (Bea et al, 2013; Zhang et al, 2014) overexpress genes with proliferation and cell cycle regulation. Within lymphoid malignancies, NSD2 mutations (p.E1099K) are implicated in altered global methylation and chromatin dysfunction leading to aberrant gene expression and are pathogenically relevant (Oyer et al, 2014) . Given that the mechanistic relationship between concordant TP53 and NSD2 mutations to influence ibrutinib resistance and MCL transformation is unclear, we believe that larger studies with ibrutinib-resistant MCL are needed to explore our finding. It is possible that the negative prognostic impact of NSD2 mutations in MCL is similar to that observed in myeloma (Martinez-Garcia et al, 2011) . Point mutations in NSD2 are recurrent in MCL (Zhang et al, 2014) , and can alter the methylation profile in MCL (Oyer et al, 2014) . We also noted a low frequency of EP300 and KM2TD (MLL2) genes in <20% samples at progression and this was similar to reports from ibrutinib resistant CLL (Burger et al, 2016) .
Consistent with previous report (Delfau-Larue et al, 2015), we observed CDKN2A alterations in 58% of patients at disease progression. In contrast to one previous report (Rahal et al, 2014) , we did not observe BIRC3, TRAF2 and MAP3K14 (NIK) mutations at any time point. The frequency of NOTCH2 and NOTCH1 mutations were low at progression. These findings may suggest that some of these mutations may not play a major role in mediating ibrutinib resistance in MCL; however, this aspect needs further validation in a large sample size with matched germline controls. Finally, we noted UBR5 mutations (Meissner et al, 2013) in a fraction of patients and these mutations were mutually exclusive with mutations of NSD2 and TP53 in most cases. UBR5 can regulate TP53 levels (Smits, 2012) and activity and therefore it is possible that UBR5 mutations might have influenced TP53 levels and thus contributed to ibrutinib resistance. We provided the first evidence of the correlation of acquired TP53 and NSD2 gene mutations in progression and/or blastoid transformation in MCL on ibrutinib. Although our mutation results are from a small sample size and require further validation in large patient cohort, we believe that our data significantly add to the previous reports on ibrutinib resistance in MCL showing the role of the tumour microenvironment (Jayappa et al, 2017; Zhao et al, 2017) , MAP3K14alterations (Rahal et al, 2014) and mutations in chromatin modifier genes, such as NSD2 (Meissner et al, 2013), in MCL progression. One of the limitations of the mutation data reported in our study is due to the lack of matched germline samples for all samples, therefore the copy number data has a noisy background, especially the LOH calling, and therefore we focused on the deep deletions and high copy number gains, which had a high signal/noise ratio.
In summary, ibrutinib-refractory MCL patients are a distinct therapeutic challenge, as these patients exhibit poor survival and lack an optimal management strategy. These patients should be best treated with clinical trials or with multimodality treatments (including chemoimmunotherapy followed by SCT, CAR-T therapy or with venetoclax-based regimens). It is possible that an association of TP53 and NSD2 mutations exists in patients who develop disease progression and blastoid transformation after treatment on ibrutinib. Finally, our results provoke questions on some unmet needs in the field of MCL, blastoid transformation, second cancers after ibrutinib, clonal evolution on ibrutinib, role of NSD2, TP53 and UBR5 mutations and developing an optimal management of ibrutinib-refractory MCL.
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Key Points
1 After a median of 3 years follow-up after ibrutinib discontinuation, patients who progressed/transformed (n = 41) on ibrutinib have a median survival of 9 months. 2 Deep targeted sequencing in 5 paired samples suggested that somatic mutations of TP53 and NSD2 correlated with disease progression/blastoid transformation.
3 BTK gene mutations were observed in patients who progressed on ibrutinib 2/12(17%) and none had PLCG2 mutations.
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